TargetBeta
P2RX3
purinergic receptor P2X 3 · also P2X3 · Purinergic receptors P2X
2 programs in company-led studies act on P2RX3, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| camlipixant | GlaxoSmithKline | phase 3 | 163 running | – | the company's pipeline |
| TCR1672 | Sino Biopharmaceutical | phase 2 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Chronic Cough, 2 programs
- Cough, 1 program
- Dermatitis, Atopic, 1 program
- Irritable Bowel Syndrome, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 9, 2027camlipixant · GlaxoSmithKline · phase 3 · NCT07519395
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.